news
Sanofi and DiCE Molecules enter research collaboration
16 March 2016 | By Victoria White
Sanofi and DiCE Molecules have entered a five-year global collaboration to discover potential new therapeutics for up to 12 targets...
List view / Grid view
Sanofi
news
Sanofi and Warp Drive Bio team up to discover oncology therapeutics and antibiotics
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...
news
Sanofi and Innate Pharma team up for NKp46-bispecific NK cell engagers
11 January 2016 | By Victoria White
The companies will work together on the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate and Sanofi's proprietary bispecific antibody format as well as tumour targets...
news
Mimetas awarded funding for organ-on-a-chip neurotoxicity models
22 December 2015 | By Victoria White
The funding is awarded in the context of the Neuratect CRACK IT Challenge to support development of better predictive, high-throughput, animal-free models for neurotoxicity of medicines and chemicals...
news
Sanofi and AstraZeneca exchange 210,000 chemical compounds
20 November 2015 | By Victoria White
The compound exchange represents a novel, open innovation model of collaboration between the two companies.
news
Sanofi and BioNTech enter cancer immunotherapy collaboration
3 November 2015 | By Victoria White
The collaboration will leverage the scientific expertise of the two organisations to discover and develop up to five cancer immunotherapies...
news
Regeneron and Sanofi launch major immuno-oncology collaboration
28 July 2015 | By Victoria White
Regeneron and Sanofi have entered into a new global collaboration to discover, develop and commercialise new antibody cancer treatments in immuno-oncology...
news
Sanofi exercises option on second therapeutic programme with Selecta Biosciences to develop a treatment for coeliac disease
13 May 2015 | By Victoria White
Under the terms of an existing agreement with Selecta, Sanofi has exercised its option to an exclusive license to develop a treatment of coeliac disease...
news
Innate Pharma and Sanofi collaborate to develop new Antibody Drug Conjugates
16 April 2015 | By Victoria White
Innate Pharma and Sanofi are to collaborate to apply Innate’s site-specific conjugation technology to the development of new Antibody Drug Conjugates (ADC)...
news
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
news
Evotec and Sanofi discuss major multi-component strategic collaboration
3 December 2014 | By Evotec
Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.
news
Sanofi and MyoKardia announce groundbreaking collaboration to develop targeted therapies for patients with genetic heart disease
19 September 2014 | By Sanofi
Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease...
news
Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
12 August 2014 | By Sanofi
Sanofi and MannKind Corporation announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes...
news
Myriad announces diabetes collaboration with Sanofi
24 June 2014 | By Myriad RBM
Myriad Genetics announced that Myriad RBM has entered into a research collaboration with Sanofi...
news
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...